Lungpacer Medical Appoints Steven Pfanstiel as Chief Financial Officer
Summary
Lungpacer Medical announced the appointment of Steven Pfanstiel as Chief Financial Officer. Pfanstiel brings nearly 25 years of financial and operational leadership across medical device, biotechnology, and healthcare industries, including prior CFO roles at publicly traded companies. He joins Lungpacer at a pivotal stage as the company accelerates commercialization of its FDA-approved AeroPace System for ventilator weaning and advances its second product, AeroNova, through clinical development.
Why it matters
This strategic hire signals Lungpacer's transition from a development-stage company to a commercial operation scaling its neurostimulation therapy in the critical care market. Pfanstiel's experience guiding healthcare companies through commercialization, operational scaling, and strategic financing is well-aligned with Lungpacer's need to capitalize on its FDA approval and established Medicare reimbursement pathway.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial